PT-141: Complete Research Guide 2026
PT-141: Complete Research Guide 2026
PT-141 occupies a unique position in peptide research — it’s one of the few synthetic peptides that has navigated the full journey from laboratory discovery to FDA approval, providing researchers with both extensive preclinical data and clinical trial evidence. As a neurosurgeon with expertise in CNS biology, I find its central nervous system mechanism particularly interesting. This guide covers everything researchers need to know about PT-141 (Bremelanotide), from its melanocortin receptor biology to its research applications.
What Is PT-141?
PT-141 (scientific name: Bremelanotide) is a synthetic cyclic heptapeptide derived from Melanotan II, itself an analog of alpha-melanocyte stimulating hormone (α-MSH). Its peptide sequence is cyclo(Nle4, D-Phe7)-α-MSH(4-10) — a modification that confers metabolic stability not present in the native hormone. PT-141 is classified as a melanocortin receptor agonist, specifically targeting MC3R and MC4R receptors expressed in the central nervous system.
What distinguishes PT-141 from most other peptides studied for autonomic function is its mechanism: rather than acting on peripheral vasculature or endothelial cells, PT-141 works centrally through hypothalamic and limbic brain circuits. This CNS-mediated mechanism has been the focus of extensive research and clinical development.
Mechanism of Action
PT-141’s biological activity flows through the melanocortin system:
- Melanocortin Receptor Agonism: PT-141 selectively binds MC3R and MC4R receptors, which are expressed in hypothalamic nuclei including the paraventricular nucleus (PVN) and arcuate nucleus — brain regions governing autonomic and neuroendocrine regulation.
- Central Nervous System Pathway: Unlike peripherally-acting compounds, PT-141’s activity is primarily mediated through the CNS. Research using melanocortin receptor knockout models has helped delineate which receptor subtypes mediate specific effects.
- Downstream Signaling: MC4R activation triggers cAMP signaling cascades within hypothalamic neurons, modulating downstream neurotransmitter release and autonomic nervous system output.
- Melanocyte Stimulation: As an α-MSH analog, PT-141 also binds peripheral MC1R on melanocytes, contributing to pigmentation effects observed in early research — a characteristic shared with its precursor Melanotan II.
- Interaction with Opioid Pathways: Some research suggests cross-talk between melanocortin and opioid receptor systems in mediating PT-141’s neurological effects, though this pathway requires further characterization.
Key Research Findings
Clinical Development History
PT-141’s path from research peptide to approved pharmaceutical is instructive. Melanotan II (MT-II) was developed at the University of Arizona in the 1980s as a potential tanning agent. During human studies, researchers observed unexpected autonomic effects — leading to identification of MC receptor subtypes involved and subsequent development of PT-141 as a more selective compound (Diamond et al., 2004, International Journal of Impotence Research).
FDA Approval: Bremelanotide (Vyleesi)
In June 2019, the FDA approved Bremelanotide (PT-141, brand name Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women — making it only the second approved treatment for this indication. The approval was based on two Phase 3 trials (RECONNECT studies) showing statistically significant improvements in desire and reductions in distress. This clinical dataset provides researchers with substantial human pharmacokinetic and safety data.
Melanocortin Receptor Biology
PT-141 has been instrumental in delineating the roles of different melanocortin receptor subtypes. Studies using PT-141 and selective MC4R antagonists have helped researchers map the functional anatomy of the hypothalamic melanocortin system (Pfaus et al., 2007, Journal of Sexual Medicine).
Autonomic and Cardiovascular Effects
Research has characterized PT-141’s hemodynamic profile. Studies show transient blood pressure increases following administration in clinical trials, mediated through central cardiovascular regulatory circuits. This cardiovascular pharmacology has been an active research area for understanding MC receptor distribution in autonomic control.
Neuropigmentation and MC1R Research
Early Melanotan/PT-141 research provided important data on MC1R physiology and the molecular biology of melanogenesis — contributing to broader understanding of pigmentation biology and UV-protective mechanisms.
Research Applications
- Melanocortin receptor biology: MC3R and MC4R pharmacology studies
- Hypothalamic neuroscience: CNS autonomic regulation research
- Neuroendocrinology: Peptide hormone CNS signaling
- Pigmentation biology: MC1R and melanogenesis research
- Autonomic physiology: Cardiovascular regulation through central pathways
- Drug development models: CNS peptide agonist pharmacokinetics
Frequently Asked Questions
What is PT-141?
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-MSH that acts as an agonist at melanocortin receptors MC3R and MC4R in the central nervous system.
How does PT-141 work?
PT-141 activates melanocortin receptors in the brain’s hypothalamic regions through a central nervous system pathway, distinct from peripheral vascular mechanisms.
What melanocortin receptors does PT-141 target?
PT-141 primarily targets MC3R and MC4R receptors expressed in hypothalamic and limbic brain regions involved in autonomic regulation.
Has PT-141 been approved for clinical use?
Bremelanotide (Vyleesi) was FDA-approved in 2019 for HSDD in premenopausal women — one of the few peptides with regulatory approval for a CNS-mediated indication.
What is PT-141’s relationship to Melanotan II?
PT-141 was developed from Melanotan II, a synthetic analog of alpha-MSH, as a more selective compound after researchers identified autonomic receptor effects during MT-II studies.
Where can researchers find PT-141 for laboratory studies?
Research-grade PT-141 is available from specialized peptide suppliers. BLL Peptides provides pharmaceutical-grade PT-141 with COA documentation for laboratory research.
Related Research
- PT-141 Research: Melanocortin Mechanisms
- PT-141 Melanocortin Receptor Research
- Semax Neuropeptide Research
Where to Find PT-141 for Research
Laboratory research with PT-141 requires pharmaceutical-grade material with verified receptor-binding activity. BLL Peptides offers research-grade PT-141 with 98%+ purity and full COA documentation. For research use only.
About the Author: Dr. James Nguyen is a board-certified neurosurgeon with training from Yale University and over a decade of experience in neurosurgery and peptide research science. He serves as scientific advisor to BLL Peptides.
Disclaimer: This content is intended for research purposes only. BLL Peptides products are not intended for human consumption.